The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in the Middle East & Africa was valued at USD 328.59 million in 2022 and estimated to be growing at a CAGR of 6.69%, to reach USD 454.23 million by 2027.
The rising prevalence of acute ischemic stroke is driving the acute ischemic stroke treatment and diagnostics market for diagnostic and surgical treatments in the Middle East and Africa. Also, the acute ischemic stroke diagnosis and treatment market is further estimated to be growing due to an increase in surgical procedures in treating stroke, cerebral ischemic cases, and rising healthcare spending.
In addition, the advanced technology used in surgeries and the growing demand for minimally persistent procedures are the key factors expected to fuel the market growth. Furthermore, the aging population, the increased need for minimally invasive surgery, and rising medical expenditures propel the acute ischemic stroke diagnostic and treatment market forward.
The growing population is significantly influencing the market growth, is the expanding geriatric population in both established and emerging countries, as older individuals are more susceptible to stroke than the younger population. On the other hand, rising tobacco consumption and diabetes prevalence in an aging population are influenced by the market. Furthermore, the acute ischemic stroke diagnostic and treatment market is projected to develop significantly due to growing awareness of stroke and accessible treatment choices, favorable government efforts, and rapid technological advances.
Excessive usage of drugs for the treatment of ischemic stroke and the high cost of surgical procedures are two factors limiting the market growth. In addition, the numerous concerns connected with product development and production may hamper the market’s growth for acute ischemic stroke diagnostics and treatment. In some developing countries, a lack of sufficient awareness is a barrier to market expansion.
This research report on the MEA Acute Ischemic Stroke Treatment & Diagnosis Market has been segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
Geographically, the Middle East and Africa are projected to record a moderate share in the global acute ischemic stroke diagnosis and treatment market during the forecast period. The demand for both diagnostic and surgical treatments in acute stroke is being driven by the increased prevalence of acute ischemic stroke patients, technological developments in surgical techniques, and an aging population.
Key market players in the region are showing a greater focus on health research and development, which is expected to provide lucrative growth opportunities to the market growth. The Middle East is the largest market within this area, accounting for a substantial share due to considered disposable income. However, Africa is anticipated to be the fastest-growing area due to its large population and rising incidence of different cardiovascular diseases such as ischemic stroke.
Africa held the largest share of the MEA acute ischemic stroke diagnosis and treatment market in 2020. Increasing research and development activities, improving the healthcare sector, and supportive government policies are propelling the market growth.
Furthermore, the market in Saudi Arabia is predicted to be expanding during the forecast period, and it is the world’s largest market for stroke diagnosis and treatment. On the other hand, Egypt is predicted to develop at a stable rate over the forecast period in the Middle East and Africa markets. The market in the rest of the Middle East and Africa is expected to grow slowly but steadily. The expansion of the acute stroke diagnosis and treatment market in the Middle East and Africa is driven by significant investments in research and development and numerous government initiatives.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the MEA Acute Ischemic Stroke Diagnosis & Treatment Market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com